Related Experiment Videos
Insights
Infant apnea syndrome is linked to higher cerebrospinal fluid (CSF) beta-endorphin levels. Naloxone, a narcotic antagonist, significantly reduced apneas in infants with elevated beta-endorphin levels.
Area of Science:
- Neonatal Medicine
- Neuroscience
- Pharmacology
Background:
- Infant apnea syndrome is a significant clinical concern.
- Cerebrospinal fluid (CSF) beta-endorphin levels in infants with apnea syndrome have not been extensively studied.
Purpose of the Study:
- To investigate the association between CSF beta-endorphin levels and infant apnea syndrome.
- To determine the therapeutic potential of naloxone in managing apnea in infants with elevated CSF beta-endorphin.
Main Methods:
- Measured CSF beta-endorphin levels in 16 infants with apnea syndrome and 34 controls.
- Administered continuous low-dose naloxone infusion to three infants with apnea and abnormal beta-endorphin levels.
- Conducted polysomnography to assess apnea and respiratory pauses during naloxone infusion.
Main Results:
- Infant apnea syndrome patients exhibited significantly higher CSF beta-endorphin levels (14.7 pmol/L) compared to controls (6.9 pmol/L).
- Naloxone infusion led to a significant reduction in apneas and respiratory pauses in infants with elevated CSF beta-endorphin.
- No significant change in apnea occurrence was observed in a patient with normal CSF beta-endorphin levels during naloxone infusion.
Conclusions:
- Elevated CSF beta-endorphin levels may play a role in the pathophysiology of infant apnea syndrome.
- Naloxone, a narcotic antagonist, shows promise as a therapeutic agent for managing apnea in affected infants.
- Further research is warranted to elucidate the precise mechanisms and optimize therapeutic strategies.
Abstract:
Cerebrospinal fluid (CSF) beta-endorphin levels were determined in 16 patients with infant apnea syndrome and 34 control patients. A statistically significant difference (P less than or equal to .0001) was found with the infant apnea syndrome patients having beta-endorphin levels of 14.7 +/- 1.2 pmol/L (mean +/- SE) and the controls having levels of 6.9 +/- 0.6 pmol/L (mean +/- SE). To test whether these elevated CSF beta-endorphin levels were the result or the possible cause of the apneas, three patients with infant apnea syndrome and abnormal CSF beta-endorphin levels participated in a study to determine whether a continuous low-dose infusion (10 micrograms/kg/h) of the narcotic antagonist naloxone would reduce the occurrence of apneas and respiratory pauses during all-night polysomnogram recordings. A fourth patient with documented apneas but normal CSF beta-endorphin levels was also studied while on a regimen of naloxone. In the patients with infant apnea syndrome and abnormal CSF beta-endorphin levels, a significant (P less than or equal to .05) reduction in apneas and respiratory pauses occurred during naloxone infusion. There was no change in the occurrence of apneas or respiratory pauses during naloxone infusion in the patient with normal CSF endorphin levels. Abnormal CSF levels of endorphins may play a role in apneas of infancy and may be amenable to therapy with narcotic antagonists.